Buy or sell PIQUR Therapeutics stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

PIQUR Therapeutics Stock

PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.

About PIQUR Therapeutics Stock

PIQUR is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the University of Basel, focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. Both PI3K and mTOR are clinically validated drug targets in oncology. PIQUR has a secured patent scope protecting many chemical compounds.

Funding History

August 2013$5.0M
March 2014$32.0M
July 2015$19.0M
September 2017$29.8M


Chief Scientific Officer

Doriano Fabbro

Head BD & Communications

Tatsuo Satoh

Head Drug Discovery

Paul Hebeisen

Head of Preclinical Safety & Toxicology

Robert Ettlin


Melanie Rolli


Martin Gasser

Head QA

Christine Wurz

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from PIQUR Therapeutics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 190K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: